Randomised clinical trial: The benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B

M. G. Ghany, J. J. Feld, X. Zhao, T. Heller, E. Doo, Y. Rotman, P. Nagabhyru, C. Koh, D. E. Kleiner, E. C. Wright, T. J. Liang, J. H. Hoofnagle

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Combination antiviral therapy holds the promise of increasing response rates while decreasing antiviral resistance, but has yet to be shown to be beneficial or necessary in chronic hepatitis B. Aim: To evaluate the benefit of combination therapy with adefovir and lamivudine versus adefovir alone in maintaining virological, biochemical and histological responses. Methods: Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks. Study endpoints were (i) maintained virological (HBV DNA

Original languageEnglish (US)
Pages (from-to)1027-1035
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume35
Issue number9
DOIs
StatePublished - 2012
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Randomised clinical trial: The benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B'. Together they form a unique fingerprint.

Cite this